Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors
B. Davies; N. Guan; A. Logie; C. Crafter; L. Hanson; V. Jacobs; N. James; P. Dudley; K. Jacques; B. Ladd; C. M. D'cruz; M. Zinda; J. Lindemann; M. Kodaira; K. Tamura; E. L. Jenkins
- 作者B. Davies; N. Guan; A. Logie; C. Crafter; L. Hanson; V. Jacobs; N. James; P. Dudley; K. Jacques; B. Ladd; C. M. D'cruz; M. Zinda; J. Lindemann; M. Kodaira; K. Tamura; E. L. Jenkins
- 文件大小1429.51KB
- 发表时间2015
- DOI10.1158/1535-7163.MCT-15-0230